Formed as a spin-out of iPierian the year before that firm was acquired by Bristol Myers Squibb, True North Therapeutics is a clinical stage biotechnology company developing novel products that selectively inhibit the Complement System to treat certain rare diseases. The companys lead product candidate, TNT009, is designed to selectively inhibit a target in the Classical Complement pathway for the treatment of cold agglutinin disease, warm autoimmune hemolytic anemia, antibody-medicated rejection, bullous pemphigoid, and other rare diseases. True Norths antibody drug development is focused on the treatment of certain rare diseases mediated by the Complement system in hematology, transplantation, and dermatology. In May 2017 it was announced that Bioverativ - a recent spin out of Biogen Idec (both SBIR involved when they were startups) would acquireTrue North for $400M upfront plus earnouts
